Zeelab aims to turn a low‑price promise into a ₹200 Cr business by reshaping India’s pharmacy supply chain, founder‑CEO Rohit Mukul says. The startup logged roughly ₹110 Cr in FY26 revenue and now targets double that figure for FY27 while keeping medicines cheap enough to fit a daily‑wage budget.
Founder’s thesis and market backdrop
After a stint at the London School of Economics, Mukul returned to study India’s drug ecosystem and saw a simple problem: too many middlemen. A tablet that costs ₹10 at the factory can end up as a ₹100 purchase for a patient, he explained.
His diagnosis framed the company’s mission. By cutting out unnecessary layers, the firm can sell a diclofenac gel that normally retails for ₹150 at a price near ₹25. “The emotional impact is more than the ₹125 saved; it shows people they’ve been overpaying,” he said.
Business model and store strategy
The firm opened its first outlet in Delhi’s Rohini in April 2020, a location chosen for convenience rather than expansion ambition. Early traction led the team to try franchising, but the model proved misaligned with the low‑price promise because franchisees struggled to keep inventory funded.
Switching to company‑owned stores gave it tighter control over stock and pricing. The typical outlet is about 200 sq ft, standardized in layout and product mix, allowing the chain to keep rent and staffing costs modest while placing stores near customers.
Omnichannel advantage and growth plans
Within two months of the first brick‑and‑mortar, the business launched an online platform, and today the two channels each contribute roughly half of total sales. Stores act as more than retail points; they serve as trust anchors and fulfilment hubs for digital orders.
A shopper can order a product not on the shelf and have it delivered, while an online buyer can pick up or return items at a nearby outlet. Mukul describes this as an “unlimited shelf,” where the physical network fills gaps in the digital catalogue.
With about 300 stores and processing 10,000 orders daily, the chain plans to offer 60‑minute delivery in roughly 30 cities by plugging logistics partners into its retail mesh. The approach avoids building a separate warehouse empire, leveraging existing storefronts for speed.
Related: Medulance Raises ₹24 Cr for Emergency Network Expansion
The model relies on trust.
The strategy of dense micro‑markets—concentrating several stores in a single neighbourhood—creates a feedback loop. Customers repeatedly see the brand, trust builds, and repeat purchases rise, especially for chronic medicines that need monthly refills. This local saturation also shortens the distance between inventory and buyer, lowering fulfilment costs.
From a broader view, the combination of low price and tight distribution could reshape how Indian consumers think about pharmacy access. If the model proves scalable, it may pressure traditional chains and public schemes to rethink their own logistics, pushing the whole market toward greater efficiency.
Challenges and metrics ahead
The company’s biggest rival is the government‑run Jan Aushadhi network, which also markets affordable drugs. While Jan Aushadhi has raised price awareness, the firm must differentiate on availability, convenience and service, not just cost.
Scaling the store network raises fixed‑cost concerns: rent, staff, inventory and working capital will climb. To justify expansion, the company will need to track revenue per outlet, break‑even timelines and sales growth at mature locations.
Customer repeat rates are another litmus test. The firm claims that a first‑time buyer often returns for months, a pattern that can reduce acquisition spend if gross margins stay healthy after accounting for procurement and fulfilment expenses.
Finally, the omnichannel model must prove profitable. Stores should lower online fulfilment costs, improve delivery times and generate enough incremental orders to offset their operating overhead.
In FY27 the company hopes to hit the earlier target, banking on both online momentum, July 2026 revenue was double that of July 2025, and continued store roll‑out. Whether the dual‑channel engine can sustain margins while keeping prices low remains the central question for investors and regulators alike.
